DDInter889 DDInter1082
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Hydroflumethiazide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Hydroflumethiazide {u} (Compound) resembles {v} (Compound) Hydrochlorothiazide
Hydroflumethiazide {u} (Compound) treats {v} (Disease) hypertension
Hydroflumethiazide {u} (Compound) binds {v} (Gene) SLC12A3
Hydroflumethiazide {u} (Compound) upregulates {v} (Gene) RGS2
Hydroflumethiazide {u} (Compound) is included by {v} (Pharmacologic Class) Thiazides
Hydroflumethiazide {u} (Compound) downregulates {v} (Gene) USP22
Hydroflumethiazide {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Hydroflumethiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyoscyamine
Hydroflumethiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound)
Hydroflumethiazide (Compound) treats hypertension (Disease)
Hydroflumethiazide (Compound) binds SLC12A3 (Gene)
Hydroflumethiazide (Compound) upregulates RGS2 (Gene)
Hydroflumethiazide (Compound) is included by Thiazides (Pharmacologic Class)
Hydroflumethiazide (Compound) downregulates USP22 (Gene)
Hydroflumethiazide (Compound) causes Agranulocytosis (Side Effect)
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium